Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 12, 2006, Pages 1231-1238

  Yu, Jun Xian ^a   Zhang, Yin Di ^a   Yin, Xiao Xing ^a   Shen, Jian Ping ^a   Qiu, Jun ^a   Yin, Hong Lin ^b   Jiang, Shao Jun ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Advanced glycation end products; Aldose reductase; Bendazac lysine; Diabetic peripheral neuropathy; Motor nerve conduction velocity; Myelinated nerve fibre; Na+ K+ ATPase; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDEHYDE REDUCTASE; BENDAZAC LYSINE; EPALRESTAT; GLUCOSE; GLUTATHIONE PEROXIDASE; GLYCOSYLATED HEMOGLOBIN; INSULIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; MOTOR NERVE CONDUCTION; MYELINATED NERVE; NEUROPROTECTION; NONHUMAN; POLYDIPSIA; POLYURIA; RAT; STREPTOZOCIN DIABETES;

ALDEHYDE REDUCTASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; ERYTHROCYTES; GLUTATHIONE PEROXIDASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; INDAZOLES; INSULIN; MALE; MYELIN SHEATH; NA(+)-K(+)-EXCHANGING ATPASE; PAIN; RATS; RATS, SPRAGUE-DAWLEY; SURAL NERVE;

EID: 33845518676     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04515.x     Document Type: Article

References (42)

1. Pittenger G, Vinik A. Nerve growth factor and diabetic neuropathy. Exp. Diabesity Res. 2003; 4: 271-85.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on thedevelopment and progression of neuropathy in the Diabetes Control and Complications Trial. Ann. Intern. Med. 1995; 122: 561-8.
3. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1997; 40: 271-81.
4. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 2003; 31: 1423-5.
5. Gries AF. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications. Diabetes Res. Clin. Pract. 1995; 28 (Suppl.): S201-7.
6. +-ATPase and diabetes. Exp. Diabesity Res. 2004; 5: 37-50.
7. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-20.
8. The St Thomas' Diabetic Study Group. Failure of improved glycaemic control to reverse diabetic autonomic neuropathy. Diabet. Med. 1986; 3: 330-4.
9. Missiroli A, Ricci F, Pocobelli A, Cedrone C, Cerulli L. Use of bendazac lysine to limit protein deposition on soft contact lenses in vitro. CLAO J. 1991; 17: 126-8.
10. Schmut O, Hofmann H. Studies on the activity of Bendalina (bendazac L-lysine salt) as a scavenger of hydroxyl and superoxide radicals. Wien Klin. Wochenschr. 1985; 97: 819-22.
11. Iuliano G, Menzione Y, Apponi-Battini G, Costagliola C. Inhibition of rat lens aldose reductase by bendazac l-lysine salt. Enzyme 1989; 42: 235-7.
12. Chen X-X, Zhang Y-D, Shen J-P, Qiu J. Phamacokinetics of bendazac lysine in 10 Chinese young men. Acta Pharmacol. Sin. 1997; 18: 109-11.
13. Yin XX, Zhang YD, Shen JP et al. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. Acta Pharmacol. Sin. 2005; 26: 721-8.
14. Tsugawa T, Shinohara R, Nagasaka A et al. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats: Treatment with an aldose reductase inhibitor. J. Endocrinol. 2004; 181: 429-35.
15. Iso K, Tada H, Kuboki K, Inokuchi T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J. Diabetes Complications 2001; 15: 241-4.
16. Apfel SC, Arezzo JG, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994; 634: 7-12.
17. Coste TC, Gerbi A, Vaque P, Pieroni G, Raccah D. Neuroprotective effect of docosahexaenoic acid-enriched phospholipids in experimental diabetic neuropathy. Diabetes 2003; 52: 2578-85.
18. Blownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 1985; 34: 938-41.
19. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 1986; 314: 403-8.
20. Ramzi SC, Vinay K, Tucker C. Pathologic Basis of Disease, 6th edn. WB Saunders, Philadelphia. 1999.
21. Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 2004; 47: 718-24.
22. Tomlinson DR, Stevens EJ, Diemel LT. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol. Sci. 1994; 15: 293-7.
23. Cameron NE, Cotter MA, Hohman TC. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide metabolism in the neurovascular deficit of diabetic rats. Diabetologia 1996; 39: 172-82.
24. Greene DA, Steven MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur. J. Pharmacol. 1999; 375: 217-23.
25. Nagamatsu M, Nickander KK, Schmelzer JD et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-7.
26. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 1991; 40: 873-7.
27. Hermenegildo C, Raya A, Roma J, Romero FJ. Decreased glutathione peroxidase activity in sciatic nerve of alloxan-induced diabetic mice and its correlation with blood glucose levels. Neurochem. Res. 1993; 18: 893-6.
28. Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-15.
29. Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C et al. GSH transport in itochondria: Defense against TNF induced oxidative stress and alcohol-induced defect. Am. J. Physiol. 1997; 273: G7-17.
30. Martensson J, Lai JC, Meister A. High-affinity transport of glutathione is part of a multicomponent system essential for mitochondrial function. Proc. Natl Acad. Sci. USA 1990; 87: 7185-9.
31. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl) lysine in human tissues in diabetes and aging. J. Clin. Invest. 1997; 99: 457-68.
32. Marques C, Ramalho JS, Pereira P, Mota MC. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc. Ophthalmol. 1995; 90: 395-404.
33. Takeda H, Higashi T, Nishikawa T et al. Release of fructose and hexose phosphates from perivascular cells induced by low density lipoprotein and acceleration of protein glycation in vitro. Diabetes Res. Clin. Pract. 1996; 31: 1-8.
34. +-ATPase activity. Metabolism 1990; 39: 563-7.
35. +-ATPase and its glucosylated derivative by aldose reductase inhibitor. Diabetes 1987; 36: 716-20.
36. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed. Pharmacother. 1995; 49: 269-77.
37. Hotta N, Sakamoto N, Shigeta Y, Kikkawa R, Goto Y. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: Multicenter study. Diabetic Neuropathy Study Group in Japan. J. Diabetes Complications 1996; 10: 168-72.
38. Leahy J, Bonner-Weir S, Weir G. Beta-cell dysfunction induced by chronic hyperglycemia: Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442-55.
39. Rossetti L, Giaccari A, Defronzo R. Glucose toxicity. Diabetes Care 1990; 13: 610-30.
40. Jaime AD. Treatment of the patient with diabetes: Importance of maintaining target HbA1C levels. Curr. Med. Res. Opin. 2004; 20: 1919-27.
41. Balfour JA, Clissold SP. Bendazac lysine: A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs 1990; 39: 575-96.
42. Hong-Chang. Electrophysiology detection for EMG, SCV, MCV and SEP on diabetic patients suffering peripheral neuropathy. Acta Acad. Med. Xuzhou 2000; 20: 427-8.